Pacira BioSciences
PCRX
261 hedge funds and large institutions have $1.46B invested in Pacira BioSciences in 2023 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 96 increasing their positions, 86 reducing their positions, and 38 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
12% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 86
1% more funds holding
Funds holding: 258 → 261 (+3)
8% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 38
4% more call options, than puts
Call options by funds: $6.41M | Put options by funds: $6.14M
0.09% less ownership
Funds ownership: 102.18% → 102.08% (-0.09%)
23% less capital invested
Capital invested by funds: $1.88B → $1.46B (-$427M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$33.7M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$16.6M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$12M |
| 4 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$11.2M |
| 5 |
CC
Clearline Capital
New York
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$26.2M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$25.8M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$16.9M |
| 4 |
Jennison Associates
New York
|
-$12.4M |
| 5 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$8.03M |
PCRX Hedge Fund Activity: Q3 2023 in Review
261 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2023, worth a combined $1.46B — down 23% from $1.88B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new PCRX positions and 38 closed out — a net gain of 3 holders — while 96 added to existing stakes and 86 trimmed.
The largest buyer was Macquarie Group, adding an estimated $33.7M. The largest seller was Citadel Advisors, cutting an estimated $26.2M.
- 261 institutional investors held Pacira BioSciences (PCRX) as of Q3 2023, up from 258 in Q2 2023.
- Funds reported $1.46B of Pacira BioSciences stock for Q3 2023, down 23% quarter-over-quarter.
- 41 funds opened new Pacira BioSciences positions in Q3 2023 and 38 closed out, a net change of +3 holders.
- The largest Pacira BioSciences buyer in Q3 2023 was Macquarie Group, an estimated $33.7M added.
- The largest Pacira BioSciences seller in Q3 2023 was Citadel Advisors, an estimated $26.2M sold.
Based on aggregated 13F filings for Q3 2023.